Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma

Paulette Mhawech-Fauceglia, Dan Wang, Damanzoopinder Samrao, Song Liu, Nefertiti C. Dupont, Tanja Pejovic

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives TFF3 has been found to be up-regulated at the gene and protein levels in endometrioid adenocarcinoma (EAC) when compared to uterine serous carcinoma (USC) and normal endometrium. In addition, TFF3 has been proven to be an estrogen-responsive gene and its expression level positively correlated to estrogen-receptor (ER) status in breast cancer cell culture. The aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER. Methods We evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue. 74% were type I (EAC), and 26% were type II (USC, CCC and carcinosarcoma). Results In type I carcinomas, TFF3+ expression was associated with no lympho-vascular invasion (p = 0.0131), disease status (p = 0.0132), recurrence-free survival (p = 0.0424) and overall survival (p = 0.0018). There was a positive association between TFF3 and ER (p +/ER+ was associated with low FIGO grade (p =.0122), early FIGO stage (p =.0062), absence of recurrence (p =.0037), absence of LVI (p =.0011), no lymph node involvement (p =.0116) and disease status (p =.0107). TFF3 appeared to be an independent prognostic marker in predicting recurrences (p =.046). In type II carcinomas, TFF3 failed to have a prognostic value. Conclusion 1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas. 2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type. 3-TFF3+ seems to forecast a good prognosis in type I endometrial carcinomas. Based on our data, TFF3 expression in endometrial cancer deserves further investigation.

Original languageEnglish (US)
Pages (from-to)174-180
Number of pages7
JournalGynecologic Oncology
Volume130
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

Estrogen Receptors
Adenocarcinoma
Endometrial Neoplasms
Endometrioid Carcinoma
Carcinoma
Recurrence
Trefoil Factor-3
Estrogens
Carcinosarcoma
Survival
Paraffin
Blood Vessels
Cell Culture Techniques
Lymph Nodes
Breast Neoplasms
Gene Expression
Antibodies

Keywords

  • Endometrial adenocarcinoma
  • Estrogen-receptor
  • Prognostic value
  • Trefoil factor family-3

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. / Mhawech-Fauceglia, Paulette; Wang, Dan; Samrao, Damanzoopinder; Liu, Song; Dupont, Nefertiti C.; Pejovic, Tanja.

In: Gynecologic Oncology, Vol. 130, No. 1, 07.2013, p. 174-180.

Research output: Contribution to journalArticle

Mhawech-Fauceglia, Paulette ; Wang, Dan ; Samrao, Damanzoopinder ; Liu, Song ; Dupont, Nefertiti C. ; Pejovic, Tanja. / Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. In: Gynecologic Oncology. 2013 ; Vol. 130, No. 1. pp. 174-180.
@article{9f1f83d5ca35452b8991aaaedffc6295,
title = "Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma",
abstract = "Objectives TFF3 has been found to be up-regulated at the gene and protein levels in endometrioid adenocarcinoma (EAC) when compared to uterine serous carcinoma (USC) and normal endometrium. In addition, TFF3 has been proven to be an estrogen-responsive gene and its expression level positively correlated to estrogen-receptor (ER) status in breast cancer cell culture. The aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER. Methods We evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue. 74{\%} were type I (EAC), and 26{\%} were type II (USC, CCC and carcinosarcoma). Results In type I carcinomas, TFF3+ expression was associated with no lympho-vascular invasion (p = 0.0131), disease status (p = 0.0132), recurrence-free survival (p = 0.0424) and overall survival (p = 0.0018). There was a positive association between TFF3 and ER (p +/ER+ was associated with low FIGO grade (p =.0122), early FIGO stage (p =.0062), absence of recurrence (p =.0037), absence of LVI (p =.0011), no lymph node involvement (p =.0116) and disease status (p =.0107). TFF3 appeared to be an independent prognostic marker in predicting recurrences (p =.046). In type II carcinomas, TFF3 failed to have a prognostic value. Conclusion 1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas. 2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type. 3-TFF3+ seems to forecast a good prognosis in type I endometrial carcinomas. Based on our data, TFF3 expression in endometrial cancer deserves further investigation.",
keywords = "Endometrial adenocarcinoma, Estrogen-receptor, Prognostic value, Trefoil factor family-3",
author = "Paulette Mhawech-Fauceglia and Dan Wang and Damanzoopinder Samrao and Song Liu and Dupont, {Nefertiti C.} and Tanja Pejovic",
year = "2013",
month = "7",
doi = "10.1016/j.ygyno.2013.03.030",
language = "English (US)",
volume = "130",
pages = "174--180",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma

AU - Mhawech-Fauceglia, Paulette

AU - Wang, Dan

AU - Samrao, Damanzoopinder

AU - Liu, Song

AU - Dupont, Nefertiti C.

AU - Pejovic, Tanja

PY - 2013/7

Y1 - 2013/7

N2 - Objectives TFF3 has been found to be up-regulated at the gene and protein levels in endometrioid adenocarcinoma (EAC) when compared to uterine serous carcinoma (USC) and normal endometrium. In addition, TFF3 has been proven to be an estrogen-responsive gene and its expression level positively correlated to estrogen-receptor (ER) status in breast cancer cell culture. The aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER. Methods We evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue. 74% were type I (EAC), and 26% were type II (USC, CCC and carcinosarcoma). Results In type I carcinomas, TFF3+ expression was associated with no lympho-vascular invasion (p = 0.0131), disease status (p = 0.0132), recurrence-free survival (p = 0.0424) and overall survival (p = 0.0018). There was a positive association between TFF3 and ER (p +/ER+ was associated with low FIGO grade (p =.0122), early FIGO stage (p =.0062), absence of recurrence (p =.0037), absence of LVI (p =.0011), no lymph node involvement (p =.0116) and disease status (p =.0107). TFF3 appeared to be an independent prognostic marker in predicting recurrences (p =.046). In type II carcinomas, TFF3 failed to have a prognostic value. Conclusion 1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas. 2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type. 3-TFF3+ seems to forecast a good prognosis in type I endometrial carcinomas. Based on our data, TFF3 expression in endometrial cancer deserves further investigation.

AB - Objectives TFF3 has been found to be up-regulated at the gene and protein levels in endometrioid adenocarcinoma (EAC) when compared to uterine serous carcinoma (USC) and normal endometrium. In addition, TFF3 has been proven to be an estrogen-responsive gene and its expression level positively correlated to estrogen-receptor (ER) status in breast cancer cell culture. The aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER. Methods We evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue. 74% were type I (EAC), and 26% were type II (USC, CCC and carcinosarcoma). Results In type I carcinomas, TFF3+ expression was associated with no lympho-vascular invasion (p = 0.0131), disease status (p = 0.0132), recurrence-free survival (p = 0.0424) and overall survival (p = 0.0018). There was a positive association between TFF3 and ER (p +/ER+ was associated with low FIGO grade (p =.0122), early FIGO stage (p =.0062), absence of recurrence (p =.0037), absence of LVI (p =.0011), no lymph node involvement (p =.0116) and disease status (p =.0107). TFF3 appeared to be an independent prognostic marker in predicting recurrences (p =.046). In type II carcinomas, TFF3 failed to have a prognostic value. Conclusion 1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas. 2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type. 3-TFF3+ seems to forecast a good prognosis in type I endometrial carcinomas. Based on our data, TFF3 expression in endometrial cancer deserves further investigation.

KW - Endometrial adenocarcinoma

KW - Estrogen-receptor

KW - Prognostic value

KW - Trefoil factor family-3

UR - http://www.scopus.com/inward/record.url?scp=84879123036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879123036&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.03.030

DO - 10.1016/j.ygyno.2013.03.030

M3 - Article

C2 - 23578537

AN - SCOPUS:84879123036

VL - 130

SP - 174

EP - 180

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -